ULK3
| Official symbol: | ULK3 |
| Full name: | unc-51 like kinase 3 |
| Location: | 15q24.1 |
| Also known as: | DKFZP434C131, FLJ90566 |
| Entrez ID: | 25989 |
| Ensembl ID: | ENSG00000140474 |
| Summary: | |
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
| Gscore (Amp): | 0.12 | | Gscore (Del): | 0.00 |
|
|
| Recurrently amplified in 1 cancer type(s) | |
|
| |
|
|
|
| |
Overall distribution
|
|
Tissue specific distribution
|
| |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
| Total fusion occurrence: | NA |
|
|
|
| |
|
|
|
| |
Overall
|
|
Tissue specific
|
| |
CRISPR: STRONGLY SELECTIVE
|
|
|
| |
|
|
|
| Functional class: | Kinase (protein kinase) |
| JensenLab PubMed score: | 7.82 (Percentile rank: 32.94%) |
| PubTator score: | 7.28 (Percentile rank: 34.51%) |
| Target development/druggability level: | TchemThese targets have activities in ChEMBL or DrugCentral that satisfy the activity thresholds detailed below. |
| Tractability (small molecule): | Discovery PrecedenceTargets with ligands; Targets with crystal structures with ligands |
| Tractability (antibody): | |
